<DOC>
	<DOCNO>NCT02377388</DOCNO>
	<brief_summary>Cardiovascular event main cause mortality diabetic patient , hand , acute myocardial infarction ( AMI ) , hyperglycemia increase mortality relate different pathophysiologic process . More important evidence regard effect glycemic control AMI patient prognosis contradictory , potential benefit dipeptidyl peptidase-4 inhibitor ( DPP4i ) set unknown . The aim study assess presence pleiotropic effect saxagliptin ( DPP4i ) relationship glycemic control in-hospital phase AMI .</brief_summary>
	<brief_title>Saxagliptin Acute Myocardial Infarction : Effects Platelet Function</brief_title>
	<detailed_description>Randomized clinical trial , double-blinded , placebo-controlled , single center , assess influence saxagliptin platelet aggregability type 2 diabetic patient acute myocardial infarction use dual anti platelet therapy ( DAPT ) . Others exploratory analysis include : glycemic control , infarct size , genetic analysis cholesterol metabolism . After give sign informed consent , eligible subject randomly allocate receive saxagliptin placebo , first 48 hour ( +-12 ) begin AMI . The investigator subject blind trial treatment , person involve trial conduct prepare dose study drug.The dos administer mouth , daily basis investigator . Blood sample collect investigator accord pre-specified outcome time frame . Evaluation glycemic control CGM carry investigator , include insert withdrawal device . Treatment acute event , ( AMI ) do accord routine procedure coronary care unit . Two unblinded interim safety analysis , take consideration all-cause mortality , cardiovascular mortality , hospitalization heart failure pancreatitis , develop independent investigator relate study 25 % 50 % patient complete 30-day follow-up</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>previous diagnosis type 2 diabetes mellitus , without treatment , include insulin and/or oral antidiabetic agent ; subject without previous diagnosis diabetes , HbA1c admission &gt; = 6,5 % &lt; =12 % AMI without STelevation ; use double antiplatelet therapy ; sign informed consent term GFR &lt; 30 ml/min ; HbA1c &lt; =6,5 % &gt; =12 % patient previous diagnosis diabetes ; use DPP4 inhibitor glucagon like peptide1 ( GLP1 ) analogue past 6 month ; use strong inhibitor cytochrome P450 ( CYP3A4/5 ) ou glucocorticoid ; severe systemic decompensation require insulin infusion ; Killip classification myocardial infarction grade &gt; 1 ; BNP &gt; 330 pg/mL admission ; previous history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>platelet function test</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>saxagliptin</keyword>
</DOC>